The combination of Upjohn and Mylan means that, for a change, Pfizer is getting smaller. But will the company’s new chief executive really be able to resist the urge to…
Bristol-Myers Squibb’s byzantine Checkmate-227 study yields one flop and one technical success that, in reality, counts for nothing.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.
The company insists that its sickle cell disease therapy Endari still has a future, despite questionable efficacy and the approach of new treatments.
Less than emphatic cardiovascular outcomes data leave Lilly looking vulnerable to Novo Nordisk’s competing drugs.
The keenly awaited study of Lynparza in pancreatic cancer maintenance fails to show much beyond its headline primary endpoint of progression-free survival.
A first-line Keytruda study is nominally positive, but numerous questions remain before approval can be assured.